Systematic review and meta-analysis

Renal safety of tenofovir disoproxil fumarate in hiv-infected patients

Ryan D. Cooper, Natasha Wiebe, Nathaniel Smith, Philip Keiser, Saraladevi Naicker, Marcello Tonelli

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals. Methods. MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates. Results. A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7%; 95% CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures. Conclusions. Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical.

Original languageEnglish (US)
Pages (from-to)496-505
Number of pages10
JournalClinical Infectious Diseases
Volume51
Issue number5
DOIs
StatePublished - Sep 1 2010

Fingerprint

Tenofovir
Meta-Analysis
Kidney
Safety
Randomized Controlled Trials
Library Science
Confidence Intervals
Hypophosphatemia
Therapeutics
Fumarates
Bone Fractures
Proteinuria
Acute Kidney Injury
MEDLINE

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Systematic review and meta-analysis : Renal safety of tenofovir disoproxil fumarate in hiv-infected patients. / Cooper, Ryan D.; Wiebe, Natasha; Smith, Nathaniel; Keiser, Philip; Naicker, Saraladevi; Tonelli, Marcello.

In: Clinical Infectious Diseases, Vol. 51, No. 5, 01.09.2010, p. 496-505.

Research output: Contribution to journalArticle

Cooper, Ryan D. ; Wiebe, Natasha ; Smith, Nathaniel ; Keiser, Philip ; Naicker, Saraladevi ; Tonelli, Marcello. / Systematic review and meta-analysis : Renal safety of tenofovir disoproxil fumarate in hiv-infected patients. In: Clinical Infectious Diseases. 2010 ; Vol. 51, No. 5. pp. 496-505.
@article{a195e9aac3ad47aca7f2df8c3dc56277,
title = "Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in hiv-infected patients",
abstract = "Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals. Methods. MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates. Results. A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95{\%} confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7{\%}; 95{\%} CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures. Conclusions. Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical.",
author = "Cooper, {Ryan D.} and Natasha Wiebe and Nathaniel Smith and Philip Keiser and Saraladevi Naicker and Marcello Tonelli",
year = "2010",
month = "9",
day = "1",
doi = "10.1086/655681",
language = "English (US)",
volume = "51",
pages = "496--505",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Systematic review and meta-analysis

T2 - Renal safety of tenofovir disoproxil fumarate in hiv-infected patients

AU - Cooper, Ryan D.

AU - Wiebe, Natasha

AU - Smith, Nathaniel

AU - Keiser, Philip

AU - Naicker, Saraladevi

AU - Tonelli, Marcello

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals. Methods. MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates. Results. A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7%; 95% CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures. Conclusions. Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical.

AB - Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals. Methods. MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates. Results. A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7%; 95% CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures. Conclusions. Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical.

UR - http://www.scopus.com/inward/record.url?scp=77955786301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955786301&partnerID=8YFLogxK

U2 - 10.1086/655681

DO - 10.1086/655681

M3 - Article

VL - 51

SP - 496

EP - 505

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -